Ricevi le ultime notizie sulle azioni Artelo Biosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ARTL

Ultime notizie per

ARTELO BIOSCIENCES INC

Artelo Biosciences

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Artelo Biosciences Inc

Artelo Biosciences Inc Warrants (18/06/2024)

Press Releases

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Health Care

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

News

Financing

Artelo Biosciences Announces Proposed Underwritten Public Offering

IPOs

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Management

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

ARTL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Aspire Biopharma Holdings, Inc. - Warrant

Aspire Biopharma Hldgs

Clearmind Medicine

CNS Pharma

China Pharma Holding

Enveric Biosciences

Impact BioMedical

IM Cannabis

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Jaguar Health

Lexaria Bioscience

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

PainReform

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Reviva Pharmaceuticals

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

XORTX Therapeutics

cbdMD

HC Wainwright & Co.

EF Hutton

Ladenburg Thalmann

Screenshot 2024-04-30 at 10.58.41 PM

Biotech

Interview

General

&#34;Brand New Science&#34; - This Biotech Is Entering Clinical Studies With What It Says Is Novel Science No One Else Has

Comments

Artelo Biosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO